Regulatory class, clinical buyer, and candidate access shape every medical device search.
Life sciences hiring is driven by three factors that don't apply the same way in any other industry. Modality drives the candidate profile more than any single other variable — a small molecule company, an antibody platform, and a cell or gene therapy program need fundamentally different CMC, regulatory, and clinical profiles, even when the therapeutic area is the same. Submitting candidates across modalities assumes a technical fluency that rarely transfers, and at the senior level, the mis-hire shows up in pipeline delays measured in quarters, not weeks.
Therapeutic area and stage dictate the commercial, clinical, and operational profiles. Oncology, rare disease, neurology, immunology, and metabolic disease each have their own development cycles, regulatory considerations, and commercial buyer dynamics. A clinical operations leader who's run oncology trials rarely transitions cleanly into rare disease; a commercial leader from a Phase III launch rarely transitions cleanly into a pre-revenue startup.Candidates who look right on paper across therapeutic areas often underperform when the disease biology, trial design, or commercial channel is different than what they know.
Candidate access is the third factor — and the one most often missed. The strongest life sciences candidates aren't applying to job postings. They're employed, often with significant equity or milestone-based compensation, and they take calls from recruiters they know.
CRO/CDMO/CMO candidates in particular — quality, engineering, business development — are in tight supply across the U.S. and rarely surface through inbound channels. A search led by a specialist works because the recruiter is already three steps into the relationship before the search starts. A search led by a generalist usually fails not because the candidates don't exist, but because the candidates don't take the call.
